The U.S. Food and Drug Administration has approved Nemluvio (nemolizumab) for the treatment of moderate-to-sev ...

AnaptysBio's rosnilimab faces significant competition and uncertainty. See why ANAB stock's future hinges on Feb 2025 Phase ...

Corvus Pharmaceuticals develops next-gen ITK inhibitors, with promising Phase 1 results. Read why CRVS stock can thrive in ...

According to newly published research, the exposure to nature provided by the Re-Connecting Nature forest microbe extract has ...

As a refresher, "Eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition that is very common in both children and adults," explains Kunal Malik, a board-certified ...

Zenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. Read the entire package insert before using this ...

Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) with or without asthma and allergic rhinitis in young children.

Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profileData includes complete results from ...

Corvus Pharmaceuticals, Inc. CRVS released interim data from a Phase 1 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. The trial will enroll 64 patients with ...

Corvus Pharmaceuticals (CRVS) announced interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating ...

Shares of Corvus Pharmaceuticals, Inc. CRVS +18.3% + Free Alerts rose sharply in today's pre-market trading after the company ...

atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat ...